Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 12, 2024

Introduction With the increasing prevalence of hypertension, incidence kidney diseases is also increasing, resulting in a serious public burden. Jiangya Tongluo decoction (JYTL), recognized prescription traditional Chinese medicine (TCM), commonly used to calm an overactive liver and reduce excess yang, while promoting blood flow alleviate obstructions meridians. Previous research has indicated that JYTL may help mitigate damage caused by hypertension; however, underlying mechanisms have not been thoroughly assessed. Methods First, amalgamation UPLC-QE/MS network pharmacology techniques was employed pinpoint potential active components, primary targets, crucial action treating hypertensive nephropathy (HN). Then, we spontaneous rats (SHRs) Wistar-Kyoto (WKYs) evaluate efficacy on HN with valsartan as positive reference. We conducted DCFH-DA fluorescence staining rat renal tissues detect level ROS. Western blotting immunohistochemistry were performed investigate further effect key targets signaling pathways. Results Through analysis, 189 ingredients 5 hub identified from JYTL. GSEA MitoCarta3.0 database PPI analysis revealed predominantly engages Sirt1-mitophagy pathway. Tanshinone iia, quercetin, adenosine are main for HN. In vivo validation showed could improve function, ameliorate tubulointerstitial fibrosis (TIF), mitochondrial function inhibiting ROS production regulating dynamics SHRs. treatment increase expression SIRT1, PGC-1α, Nrf1, TFAM, activate PINK1/Parkin-mediated mitophagy. Conclusion exert protective anti-fibrosis effects ameliorating SIRT1/PGC-1α-mitophagy

Language: Английский